India's indigenous coronavirus vaccine, Covaxin, has shown to generate a robust immune response in its first phase clinical trials.

A detailed immunogenicity response of the first phase trials of the vaccine has been declared by the manufacturers. Covaxin, jointly developed by Hyderabad based Bharat Biotech and ICMR has been found to be safe generating no serious adverse effects in people of all dose groups as per the results of the first phase clinical trials. ICMR has informed that the vaccine can be stored at 2 and 8-degree centigrade temperatures which also makes it compatible with the National Immunization plan.

Covaxin is one among the three coronavirus vaccine candidates being considered for emergency use authorisation in India by the Drug regulator. It is currently in its third and last phase of clinical trials with nearly 26 thousand volunteers in the age group of 18 and 55.

The ongoing trend of contraction of India’s total active cases continues. The active caseload of the country stands at 3,32,002. The share of Active Cases in the total Positive Cases has further shrunk to 3.34%.

In the last 24 hours, only 26,382 persons were found to be infected with COVID in India. In the same period, India also registered 33,813 new recoveries ensuring a net decline of 7,818 cases in the Active Caseload.

India has recorded less than 40,000 daily new cases since the last 17 days.